USP9X and hepatocellular carcinoma: Inhibition of ubiquitin activity of USP9X can enhance the cytotoxicity of cisplatin in ER-negative tumour cells [34] and increase the sensitivity of hepatoma cells to adriamycin through USP9X-dependent P53 degradation [35].